Business
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
HOUSTON, December 09, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced that dosing of ALS patients in the Company’s ALSTARS Trial of COYA 302 has commenced.
About this update from Dr. Reddy's Laboratories Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":200,"url":"https://media.zenfs.com/en/business-wire.com/783fda57fa14e70ec101c126c0f679c0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/64i8YiPp.XQzO.W0EBv3xA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/783fda57fa14e70ec101c126c0f679c0","width":480,"height":200}},"lazy":false},{"type":"text","content":"The ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being conducted at clinical sites in the United States and Canada","length":261,"tagName":"p","attribs":{}},{"type":"text","content":"Dosing of ALS patients has commenced in the ALSTARS Trial and signifies a key milestone for the Company.","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"COYA 302, a combination of proprietary low-dose IL-2 and CTLA-4 Ig, is designed to enhance the number and function of regulatory T cells while suppressing the pro-inflammatory myeloid activity that drives ALS progression.","length":221,"tagName":"p","attribs":{}},{"type":"text","content":"COYA will receive a $4.2 million milestone payment from its strategic partner, Dr. Reddy’s Laboratories (DRL), for the achievement of this milestone","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"HOUSTON, December 09, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced that dosing of ALS patients in the Company’s ALSTARS Trial of COYA 302 has commenced.","length":390,"tagName":"p"},{"type":"text","content":"Dr. Fred Grossman, the Company’s Chief Medical Officer, said, "We are very pleased that the ALSTARS Trial is underway, and we want to extend our sincere thanks to patients and their families for their participation in this important study. We believe COYA 302 represents an innovative approach to treating ALS, with a clear and well-characterized mechanism of action focused on both restoring regulatory...